Last edition
News about "Lloyd Payne"
Kinvard Bio has secured USD 2.7 million in follow-on non-dilutive funding from CARB-X to advance its novel ribosome-targeting antibiotics toward preclinical development, tackling drug-resistant infections like MRSA and cUTI.
Lloyd Payne | 29/07/2025 | By Mrinmoy Dey | 178
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members